Understanding Allogeneic (Donor -Derived) Mesenchymal Stromal Cell (MSC) Therapy

Why immune response may not be a barrier in veterinary regenerative medicine

Innate and adaptive immune system 

Feline Chronic Gingivostomatitis (FCGS), osteoarthritis, and other inflammatory diseases often leave pet parents and veterinarians searching for solutions that go beyond symptom management. One promising area of exploration? Allogeneic mesenchymal stromal cell (MSC) therapy—which uses cells donated by one animal of the same species to treat another.

A common question is: Won’t the immune system reject these cells?

This blog explores the concept of immune privilege in MSCs.

Note: Gallant’s investigational therapies are not approved for commercial use. All studies are conducted under FDA oversight.

What Does “Immune Privilege” Mean?

In immunology, “immune privilege” refers to cells or tissues that are less likely to trigger an immune response, even when introduced from a donor.

How MSCs Likely Avoid Rejection

MSCs are being evaluated for their immunomodulatory properties, meaning how they interact with the body’s own cells to balance the immune system.

Research suggests MSCs:

• Lack major histocompatibility complex (MHC) receptors that are  present on other cells and would normally trigger the body to recognize a cell as foreign and potentially initiate an immune attack
• Suppress overactive immune responses
• Modulate inflammation

Because of these properties, MSCs may avoid detection or calm immune responses that would otherwise lead to rejection.

Why This Matters for Veterinary Care

Because MSCs from healthy donors can be administered with low likelihood of immune reaction, it unlocks several advantages:

• Off-the-shelf availability
• No need for patient cell harvesting or culturing
• Consistent formulation, dosing, and delivery

These features could make MSC therapies more accessible to all pets in need.

Still Under Investigation

While early studies are promising, Gallant’s MSC therapies remain investigational and are being rigorously evaluated under FDA-authorized clinical trials. These studies are essential to better understand how MSCs behave in real-world veterinary settings.

Want to Learn More?

We’re actively enrolling pets into studies evaluating investigational MSC therapy for a variety of conditions.

Learn about our clinical trials, participation, and locations.

Disclaimer

Gallant’s investigational MSC therapies are not commercially available. These veterinary products may be available through participation in a study at a qualified clinic under FDA-authorized protocols. This blog is intended for educational purposes only and does not constitute medical advice.